Leslie Lawrence
Psychiatry · New Orleans, LANPI 1598815888
Payments from drug & device makers
Across 174 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$794
- Teva Pharmaceuticals USA, Inc.$606
- AbbVie$452
- Indivior Inc.$310
- Neurocrine Biosciences, Inc.$275
- Johnson & Johnson$275
- plus $548 from 5 others
What the payments were for
- Food & beverage$3,13496%
- Education$1264%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 46 | $794 |
| Teva Pharmaceuticals USA, Inc. | 30 | $606 |
| AbbVie | 33 | $452 |
| Indivior Inc. | 10 | $310 |
| Neurocrine Biosciences, Inc. | 15 | $275 |
| Johnson & Johnson | 11 | $275 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $262 |
| Lundbeck LLC | 7 | $142 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| Sunovion Pharmaceuticals Inc. | 4 | $57 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
How this compares
$3,260 in reported general payments places this provider in the 80th percentile of 474 psychiatry providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 39 | $111,021 |
| IngrezzaValbenazine Tosylate | 13 | $110,982 |
| AustedoDeutetrabenazine | 13 | $97,954 |
| LybalviOlanzapine/Samidorphan Malate | 30 | $46,999 |
| VraylarCariprazine Hcl | 23 | $34,415 |
| CaplytaLumateperone Tosylate | 14 | $23,722 |
| Haloperidol Decanoate | 50 | $3,792 |
| Quetiapine Fumarate | 128 | $2,938 |
| Risperidone | 69 | $2,328 |
| Hydroxyzine Pamoate | 65 | $1,804 |
| Ziprasidone Hcl | 13 | $1,388 |
| Aripiprazole | 33 | $1,133 |
| Mirtazapine | 67 | $877 |
| Bupropion XlBupropion Hcl | 56 | $836 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 74 | $833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $275 | $111,02139 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $275 | $110,98213 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $606 | $97,95413 claims |
| Alkermes, Inc.Lybalvi | $794 | $46,99930 claims |
| AbbVieVraylar | $452 | $34,41523 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $262 | $23,72214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in New Orleans
- Arwen PodestaNew Orleans$466K
- Andrew MorsonNew Orleans$56K
- James BarbeeNew Orleans$28K
- Neha KansaraNew Orleans$13K
- Erich ConradNew Orleans$9K
- Rahn BaileyNew Orleans$8K
- Nick RamandiNew Orleans$8K
- Ashley WeissNew Orleans$8K
- Ravindra ReddyNew Orleans$7K
- Paul PeltsNew Orleans$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.